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Introduction
Proteases that remodel the extracellular matrix (ECM) play
an important role in the progression of neoplasia [1].
Excessive protease activity can lead to major changes
within the microenvironment of tumour tissue to promote
cell migration, and it thereby contributes to metastasis.
Moreover, subtle changes in the levels and activities of
proteases can expose cryptic sites in ECM molecules that
alter integrin usage, and release matrix-bound growth
factors, which both potentiate proliferation and survival of
tumour cells, and induce angiogenesis [2–4]. Thus,
several of the hallmarks of tumour progression occur as a
result of alteration in protease activity within the extracellu-
lar environment of a nascent tumour [5]. Direct evidence
that inappropriate expression of both matrix metallopro-
teinases (MMPs) and serine proteases, the two main
classes of ECM-degrading proteases, is involved in
tumour progression comes from mis-expression studies in
genetically altered mice [6–8].
It is little wonder, then, that nature has devised means of
keeping ECM-degrading proteases under tight control.
Tissue inhibitors of MMPs suppress the activity of MMPs,
whereas serpins are a class of serine protease inhibitor.
The expression of these protease inhibitors is closely reg-
ulated in developmental morphogenetic processes. For
example, tissue inhibitors of MMPs control ECM remodel-
ling during mammary gland development, suppressing
excess MMP activity and therefore preventing matrix
remodelling from occurring prematurely in postlactational
involution [9,10]. However, there can be disastrous conse-
quences if the expression of matrix proteinase suppress-
ing enzymes is mis-regulated. Just as over-expression of
MMPs and serine proteases can contribute to carcinogen-
esis, so can down-regulation of their inhibitors. Levels of
one such inhibitor of serine proteases, namely maspin, are
frequently reduced or even absent in invasive cancer [11].
Maspin: a serine protease inhibitor
Maspin was identified by subtractive hybridization of
cDNAs from normal versus tumourigenic breast cells [11].
This 42-kDa protein has significant homology to serpin and
contains a carboxyl terminal reactive serpin loop domain,
which is essential for its antiprotease activity. Several fea-
tures of its expression and function, which are discussed
below, indicate that maspin is a tumour suppressor.
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First, maspin is strongly down-regulated in some cancers.
Its levels inversely correlate with the stage of malignancy
during breast cancer progression [12,13]. Moreover,
maspin levels are also reduced in prostate and oral squa-
mous carcinoma, and in mouse models of mammary
tumourigenesis [14–16]. Two mechanisms for its altered
expression in cancer have thus far been identified. The gene
that encodes maspin is silenced in some tumours through
hypermethylation at CpG islands [17]. Moreover, maspin is
under the control of p53 and may therefore not be
expressed in tumour cells with abnormal p53 function [18].
Second, recombinant maspin blocks the invasion of several
tumour cell lines in Matrigel™ culture assays [19], indicating
that it has a migration suppression function. One possible
mechanism for this is by reducing the cell surface prote-
olytic activities required for breaking and making cell–matrix
adhesions during migration [20]. Tissue plasminogen acti-
vator, localized to the cell surface, is implicated in migration
of tumour cells [21], whereas membrane type 1 MMP stimu-
lates migration of MCF7 cells [22]. An alternative possibility
is that maspin, through an unknown mechanism, prevents
invasion by increasing the strength of integrin mediated
adhesion to the ECM. Recombinant maspin elevates the
cell surface levels of α5β1 integrin in MDA-MB-435 cells,
thereby reducing their motility on fibronectin [23]. As with
many cell regulatory factors, maspin may be presented to
the cell surface by matrix molecules themselves, because it
binds collagen types I and III [24].
The migration suppression function of maspin for cancer
cells is potent, with a median effective dose of
0.2–0.3 µmol/l, and requires the reactive serpin loop [25].
Importantly, maspin also has an equally effective but quite
different function, because it blocks endothelial cell migra-
tion in culture and neovascularization in vivo, indepen-
dently of the reactive serpin loop [25]. Also implicated in
tumour angiogenesis are MMPs [26], and analogous
antiangiogenic activity is provided by a novel membrane
anchored MMP inhibitor, RECK [27]. Thus, a third tumour
suppressor activity of maspin is to inhibit angiogenesis, a
role that now appears to be extended to other classes of
protease inhibitor [28].
Maspin and tumour progression
Given all of these intriguing properties, it would be useful
to know whether maspin really can affect the progression
of tumours toward malignancy in vivo. Not many good
orthotopic models for human metastatic breast cancer are
available to study this. MCF7 breast cancer cells can grow
and metastasize from an orthotopic site [29]. In a further
model, MDA-MB-435 cells that stably express hepatocyte
growth factor rapidly metastasize to the lung [30].
However, MDA-MB-435 has now been shown to be
derived from a melanoma rather than a breast cancer, thus
reducing the number of available models for studying
metastasis from human breast tumours [31]. By contrast,
several mammary orthotopic metastatic syngeneic models
have been described for both mice and rats [32–37]. A
recent study [38] described an additional syngeneic
tumour implantation model to investigate the role of
maspin in tumour progression in vivo.
The new model involves transplantation of TM40D cells
derived from the Balb/c mammary epithelial strain FSK-4
[39] into the orthotopic site of syngeneic hosts [38].
Primary tumours develop 3–4 weeks after inoculation with
5×1 0 5 cells and become large 2 weeks later. The
tumours are aggressive, showing little encapsulation, and
metastasize to the intestine and lung in approximately
75% of cases. The model appears to be valuable, and
hopefully further studies that involve more mice and more
detailed pathology of the tumours and metastases will
eventually be forthcoming. For the purpose of the present
commentary, however, the important result concerns the
effect of maspin expression in the tumour model.
Two approaches were used in the study conducted by Shi
et al. [38]. In the first approach, maspin was transfected
into TM40D cells under the control of the strongly
expressed elongation factor promoter and stable clones
were isolated. In the second, cells infected with a retro-
virus expressing maspin and green fluorescent protein
(GFP) were selected by flow cytometry on the basis of
GFP expression. Maspin significantly reduced the percent-
age of mice that developed tumours, increased the time
taken for tumours to become established, and reduced
their growth rate. The effect was more marked using the
cells selected after viral infection. These results are
impressive but not as dramatic as those from the subse-
quent metastasis study, in which metastasis was com-
pletely abrogated by maspin expression [38]. In each case
the primary tumour was encapsulated with a fibrous
sheath, suggesting a possible mechanism for inhibition of
secondary tumour formation.
These are certainly interesting data and point to a potentially
important role for maspin as a tumour suppressor for breast
cancer in vivo. However, a significant number of questions
remain that will hopefully be resolved by future studies. First,
the data sets are very small (12 mice with TM40D implants
and only three with maspin transduced cells in the metasta-
sis study), and so statistical analysis is not really possible at
this stage. Second, control experiments using cells trans-
duced with catalytically altered maspin have not yet been
done. Finally, the mechanism responsible for maspin medi-
ated suppression of tumour growth has not been eluci-
dated; is it due to maspin’s function in blocking epithelial
cell migration or angiogenesis, or both?
Intriguingly, maspin is normally produced by myoepithelial
cells [40,41]. In the early stages of breast cancer progres-139
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sion, tumours are ensheathed by a layer of myoepithelial
cells that have tumour suppressor activity [42], and are
themselves subtended by a laminin-rich basement mem-
brane [43,44]. The transition from ductal carcinoma in situ
to malignant lesions results in loss of this myoepithelial cell
layer and consequent disappearance of the basement
membrane [42]. This myoepithelial cell and basement
membrane loss is likely to have several implications for
tumour progression. For example, cells that would nor-
mally depend on basement membrane for preventing
apoptosis [45] are selected for their ability to survive in an
inappropriate ECM environment by over-expression of
integrin signalling enzymes, such as focal adhesion kinase
[46], which is frequently up-regulated in breast cancer
[47]. A further consequence of myoepithelial cell disap-
pearance, based on the study using the new syngeneic
breast cancer model [38], is that the reduction in maspin’s
function in vivo results in an increase in serine protease
activity and thereby contributes to metastasis and/or the
associated neovascularization to feed the growing tumour.
Conclusion
We are left with a tantalizing image of maspin as a potent
tumour suppressor, both in culture and now in vivo. Hope-
fully, future studies on the structure of maspin and the mol-
ecular details of how it interacts with substrates may
ultimately yield novel therapeutics that mimic its activities.
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